{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:46:52Z","timestamp":1777852012575,"version":"3.51.4"},"reference-count":94,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Health Informatics J"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Digital health technologies are often subject to regulatory requirements. Regulatory auditing processes are complex but necessary to guarantee quality, efficacy and safety of patients. Evolvements such as digitalized clinical trials, and digital biomarkers require a constant adaption of regulatory frameworks.\n                    <jats:bold>Objective:<\/jats:bold>\n                    This review aims to provide an overview on current regulations and standards for digital therapeutics and digital biomarkers, from technical development to market access.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We conducted an unstructured literature review to identify the relevant guidelines, policies and standards for software based digital therapeutics and digital biomarkers.\n                    <jats:bold>Results:<\/jats:bold>\n                    The principal regulations governing software as a medical device are outlined in Chapter 21 of the Code of Federal Regulations by the US Food and Drug Administration, as well as the European Medical Device Regulation 2017\/745. Regulatory pathways, such as the DiGA, are in the process of development, particularly for digital therapeutics, which fall within the purview of software as a medical device. Qualification of (digital) biomarkers is typically voluntary but can play a significant role in the development and approval of digital therapeutics.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Fragmented, lacking and diverse regulations around digital biomarkers and digital therapeutics highlight the urge to harmonize and foster regulatory frameworks on an international level.\n                  <\/jats:p>","DOI":"10.1177\/14604582251387656","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:02:42Z","timestamp":1760054562000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Navigating through regulatory frameworks for digital therapeutics and biomarkers"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4612-4221","authenticated-orcid":false,"given":"Cinja","family":"Koller","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-9325","authenticated-orcid":false,"given":"Marc","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3276-9581","authenticated-orcid":false,"given":"Thomas","family":"H\u00fcgle","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552076221085810"},{"key":"e_1_3_5_3_2","unstructured":"FDA. What is digital health? https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/what-digital-health (2020)."},{"key":"e_1_3_5_4_2","unstructured":"World Health Organization (WHO). Global strategy on digital health 2020-2025. https:\/\/www.who.int\/docs\/default-source\/documents\/gs4dhdaa2a9f352b0445bafbc79ca799dce4d.pdf (2021)."},{"key":"e_1_3_5_5_2","unstructured":"International Medical Device Regulatory Forum (IDMRF). IMDRF terms of reference. https:\/\/www.imdrf.org\/sites\/default\/files\/2023-02\/IMDRFTermsofReference_2023%28N1ToR%29.pdf (2023)."},{"key":"e_1_3_5_6_2","unstructured":"IMDRF SaMD Working Group. Software as a medical device (SaMD): key definitions. https:\/\/www.imdrf.org\/sites\/default\/files\/docs\/imdrf\/final\/technical\/imdrf-tech-131209-samd-key-definitions-140901.pdf (2013)."},{"key":"e_1_3_5_7_2","unstructured":"DTx Alliance. Digital therapeutics definition and core principles. https:\/\/dtxalliance.org\/wp-content\/uploads\/2021\/01\/DTA_DTx-Definition-and-Core-Principles.pdf (2019)."},{"key":"e_1_3_5_8_2","unstructured":"European Medicines Agency (EMA). Medical devices. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/medical-devices"},{"key":"e_1_3_5_9_2","unstructured":"FDA. Center for devices and radiological health. https:\/\/www.fda.gov\/about-fda\/fda-organization\/center-devices-and-radiological-health (2023)."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00583-z"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2021.751629"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13529"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217750088"},{"key":"e_1_3_5_14_2","unstructured":"FDA. Qualification of medical device development tools guidance for industry tool developers and food and drug administration staff. https:\/\/www.fda.gov\/media\/87134\/download"},{"key":"e_1_3_5_15_2","unstructured":"European Medicines Agency (EMA). Questions and answers: qualification of digital technology-based methodologies to support approval of medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-answers-qualification-digital-technology-based-methodologies-support-approval-medicinal_en.pdf (2020)."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0141076820961776"},{"key":"e_1_3_5_17_2","first-page":"180","article-title":"Effects of medical device regulations on the development of stand-alone medical software: a pilot study","volume":"248","author":"Blagec K","year":"2018","unstructured":"Blagec K, Jungwirth D, Haluza D, et al. Effects of medical device regulations on the development of stand-alone medical software: a pilot study. Stud Health Technol Inform 2018; 248: 180\u2013187.","journal-title":"Stud Health Technol Inform"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.2"},{"key":"e_1_3_5_19_2","unstructured":"FDA. Overview of device regulation. https:\/\/www.fda.gov\/medical-devices\/device-advice-comprehensive-regulatory-assistance\/overview-device-regulation (2020)."},{"key":"e_1_3_5_20_2","unstructured":"European Medical Agency (EMA). About us. https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do"},{"key":"e_1_3_5_21_2","unstructured":"International Medical Device Regulatory Forum (IDMRF). About IMDRF. https:\/\/www.imdrf.org\/about"},{"key":"e_1_3_5_22_2","unstructured":"Regulation (EU) 2017\/745. of the European parliament and of the council of 5 April 2017 on medical devices amending directive 2001\/83\/EC regulation (EC) no 178\/2002 and regulation (EC) no 1223\/2009 and repealing council directives 90\/385\/EEC and 93\/42. EEC. http:\/\/data.europa.eu\/eli\/reg\/2017\/745\/oj"},{"key":"e_1_3_5_23_2","unstructured":"Code of Federal Regulations (CFR). Food and Drugs. Sect H 21. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H"},{"key":"e_1_3_5_24_2","unstructured":"FDA. How to study and market your device. https:\/\/www.fda.gov\/medical-devices\/device-advice-comprehensive-regulatory-assistance\/how-study-and-market-your-device (2022)."},{"issue":"1","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"e000066","DOI":"10.1136\/bmjsit-2020-000066","article-title":"IDEAL as a guide to designing clinical device studies consistent with the new european medical device regulation","volume":"3","author":"Fleetcroft C","year":"2021","unstructured":"Fleetcroft C, McCulloch P, Campbell B. IDEAL as a guide to designing clinical device studies consistent with the new european medical device regulation. BMJ Surg Interv Health Technol 2021; 3(1): e000066.","journal-title":"BMJ Surg Interv Health Technol"},{"key":"e_1_3_5_26_2","unstructured":"European Parliament and Council. Regulation (EU) 2023\/607 of the European parliament and of the council of 15 march 2023 amending regulations (EU) 2017\/745 and (EU) 2017\/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32023R0607"},{"key":"e_1_3_5_27_2","unstructured":"European Commission. Is your software a medical device? https:\/\/health.ec.europa.eu\/system\/files\/2021-03\/md_mdcg_2021_mdsw_en_0.pdf (2021)."},{"key":"e_1_3_5_28_2","unstructured":"FDA. Policy for device software functions and Mobile medical applications guidance for industry and food and drug administration staff. https:\/\/www.fda.gov\/media\/80958\/download (2022)."},{"key":"e_1_3_5_29_2","unstructured":"European Medicines Agency (EMA). Essential considerations for successful qualification of novel methodologies. https:\/\/www.ema.europa.eu\/en\/documents\/other\/essential-considerations-successful-qualification-novel-methodologies_en.pdf (2017)."},{"key":"e_1_3_5_30_2","unstructured":"FDA. Classify your medical device. https:\/\/www.fda.gov\/medical-devices\/overview-device-regulation\/classify-your-medical-device"},{"key":"e_1_3_5_31_2","unstructured":"ehealth suisse. Guide for app developers manufacturers and distributors practical guidance. https:\/\/www.e-health-suisse.ch\/fileadmin\/user_upload\/Dokumente\/2018\/E\/180731_Leitfaden_fuer_App_Entwickler_def_EN.pdf (2022)."},{"key":"e_1_3_5_32_2","unstructured":"Medical Device Coordinaton Group. MDCG 2019-11 guidance on qualification and classification of software in regulation (EU) 2017\/745 \u2013 MDR and regulation (EU) 2017\/746 \u2013 IVDR. 2019."},{"key":"e_1_3_5_33_2","unstructured":"FDA. Design control guidance for medical device manufacturers. https:\/\/www.fda.gov\/media\/116573\/download (1997)."},{"key":"e_1_3_5_34_2","volume-title":"An introduction to FDA\u2019s regulation of medical devices","author":"Mallis E","unstructured":"Mallis E. An introduction to FDA\u2019s regulation of medical devices. FDA. https:\/\/www.fda.gov\/media\/123602\/download"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2022.1063622"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103150"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1109\/SEHC.2012.6227011"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1109\/EMBC.2015.7318614"},{"key":"e_1_3_5_39_2","unstructured":"ISO. ISO 14971: 2019 medical devices \u2014 application of risk management to medical devices. https:\/\/www.iso.org\/standard\/72704.html (2019)."},{"issue":"4","key":"e_1_3_5_40_2","first-page":"237","article-title":"Risk management in the design of medical device software systems","volume":"36","author":"Jones PL","year":"2002","unstructured":"Jones PL, Jorgens J, Taylor AR, et al. Risk management in the design of medical device software systems. Biomed Instrum Technol 2002; 36(4): 237\u2013266.","journal-title":"Biomed Instrum Technol"},{"key":"e_1_3_5_41_2","unstructured":"ISO. ISO 13485:2016-Medical devices \u2014 quality management systems \u2014 requirements for regulatory purposes. 2016. https:\/\/www.iso.org\/standard\/59752.html"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-79"},{"key":"e_1_3_5_43_2","doi-asserted-by":"crossref","unstructured":"ISO. IEC 62304:2006\/Amd 1:2015 medical device software \u2014 software life cycle processes \u2014 amendment 1. https:\/\/www.iso.org\/standard\/64686.html (2015).","DOI":"10.1049\/ic:20060141"},{"key":"e_1_3_5_44_2","unstructured":"ISO. IEC 81001-5-1:2021 health software and health IT systems safety effectiveness and security \u2014 part 5-1: security \u2014 activities in the product life cycle [Internet]. https:\/\/www.iso.org\/standard\/76097.html#:\u223c:text=ISO-IEC81001-5-1%3A2021-Healthsoftwareand Security%E2%80%94Activitiesintheproductlifecycle (2021)."},{"key":"e_1_3_5_45_2","unstructured":"ISO. IEC 62366-1:2015 medical devices \u2014 part 1: application of usability engineering to medical devices. https:\/\/www.iso.org\/standard\/63179.html (2015)."},{"key":"e_1_3_5_46_2","volume-title":"Studies in Health Technology and Informatics","author":"Meijer W","year":"2022","unstructured":"Meijer W, Taylor A. ISO\/IEC-Standards on quality and safety of telehealth services and Mobile medical apps. In: Otero P, Scott P, Martin SZ, et al. (eds). Studies in Health Technology and Informatics. IOS Press, 2022."},{"key":"e_1_3_5_47_2","unstructured":"ISO. IEC 82304-1:2016 health software \u2014 part 1: general requirements for product safety. https:\/\/www.iso.org\/standard\/59543.html (2016)."},{"key":"e_1_3_5_48_2","unstructured":"Medical Device Coordination Group. MDCG 2020-1 guidance on clinical evaluation (MDR)\/performance evaluation (IVDR) of medical device software. https:\/\/health.ec.europa.eu\/system\/files\/2020-09\/md_mdcg_2020_1_guidance_clinic_eva_md_software_en_0.pdf"},{"key":"e_1_3_5_49_2","unstructured":"FDA. Software as a medical device (SAMD): clinical evaluation guidance for industry and food and drug administration staff. https:\/\/www.fda.gov\/media\/100714\/download (2017)."},{"key":"e_1_3_5_50_2","unstructured":"ISO. ISO 14155:2020 clinical investigation of medical devices for human subjects -- good clinical practice. https:\/\/www.iso.org\/standard\/71690.html (2020)."},{"key":"e_1_3_5_51_2","unstructured":"FDA. E6 (R2) good clinical practice: integrated addendum to ICH E6(R1) guidance for industry. 2018. https:\/\/www.fda.gov\/media\/93884\/download"},{"key":"e_1_3_5_52_2","unstructured":"FDA. Current good manufacturing practice (CGMP) regulations. https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/current-good-manufacturing-practice-cgmp-regulations (2023)."},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2023.1101476"},{"key":"e_1_3_5_54_2","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Das Fast-Track-Verfahren f\u00fcr digitale Gesundheitsanwendungen (DiGA) nach \u00a7 139e SGB V Ein Leitfaden f\u00fcr Hersteller Leistungserbringer und Anwender. https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Medizinprodukte\/diga_leitfaden.html;jsessionid=DACF4FAC0B6D661D1B6CAF4C8AA7D626.intranet262?nn=597198 (2023)."},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552076241308704"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2021.667016"},{"issue":"4","key":"e_1_3_5_57_2","first-page":"313","article-title":"Insights into insurance coverage for digital therapeutics: a qualitative study of US payer perspectives","volume":"30","author":"Lumbreras AG","year":"2024","unstructured":"Lumbreras AG, Hurwitz JT, Liang X, et al. Insights into insurance coverage for digital therapeutics: a qualitative study of US payer perspectives. J Manag Care Spec Pharm 2024; 30(4): 313\u2013325.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2020-0523"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0090-4"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1159\/000502000"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054375"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162340"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1159\/000525061"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11111519"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29206"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00415-6"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2020.511"},{"key":"e_1_3_5_68_2","unstructured":"U.S. Food & Drug Administration (FDA). About biomarkers and qualification. https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/about-biomarkers-and-qualification (2021)."},{"key":"e_1_3_5_69_2","unstructured":"FDA Health Canada United Kingdom\u2019s medicines and healthcare products regulatory agency (MHRA). Good Machine Learning Practice for Medical Device Development: Guiding Principles. 2021. https:\/\/www.fda.gov\/media\/153486\/download"},{"key":"e_1_3_5_70_2","unstructured":"FDA. Artificial intelligence\/machine learning (AI\/ML)-Based software as a medical device (SaMD) action plan. https:\/\/www.fda.gov\/media\/145022\/download?attachment (2021)."},{"key":"e_1_3_5_71_2","volume-title":"Artificial intelligence-enabled device software functions: lifecycle management and marketing submission recommendations. draft guidance for industry and food and drug administration staff","author":"FDA","year":"2025","unstructured":"FDA. Artificial intelligence-enabled device software functions: lifecycle management and marketing submission recommendations. draft guidance for industry and food and drug administration staff. FDA, 2025."},{"key":"e_1_3_5_72_2","unstructured":"IMDRF. Artificial intelligence\/machine learning-enabled. https:\/\/www.imdrf.org\/working-groups\/artificial-intelligencemachine-learning-enabled"},{"key":"e_1_3_5_73_2","unstructured":"The European Parliament and the Council of the European Union. Regulation (EU) 2024\/1689 of the european parliament and of the council of 13 June 2024 laying down harmonised rules on artificial intelligence and amending regulations (EC) no 300\/2008 (EU) no 167\/2013 (EU) no 168\/2013 (EU) 2018\/858 (EU) 2018\/1139 and (EU) 2019\/2144 and directives 2014\/90\/EU (EU) 2016\/797 and (EU) 2020\/1828 (Artificial intelligence act) (Text with EEA relevance). https:\/\/data.europa.eu\/eli\/reg\/2024\/1689\/oj (2024)."},{"key":"e_1_3_5_74_2","unstructured":"FDA. Use of real-world evidence to support regulatory decision-making for medical devices guidance for industry and food and drug administration staff. https:\/\/www.fda.gov\/media\/99447\/download (2017)."},{"key":"e_1_3_5_75_2","volume-title":"Guideline on computerised systems and electronic data in clinical trials","author":"Good Clinical Practice Inspectors Working Group","year":"2023","unstructured":"Good Clinical Practice Inspectors Working Group. Guideline on computerised systems and electronic data in clinical trials. European Medicines Agency (EMA), 2023. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-computerised-systems-electronic-data-clinical-trials_en.pdf"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.153"},{"key":"e_1_3_5_77_2","unstructured":"Clinical trials transformation initative (CTTI). https:\/\/ctti-clinicaltrials.org\/"},{"key":"e_1_3_5_78_2","unstructured":"Danish Medicine Agency. The Danish medicines Agency\u2019s guidance on the implementation of decentralised elements in clinical trials with medicinal products. https:\/\/laegemiddelstyrelsen.dk\/en\/news\/2021\/guidance-on-the-implementation-of-decentralised-elements-in-clinical-trials-with-medicinal-products-is-now-available\/\u223c\/media\/5A96356760ED408CBFA9F85784543B53.ashx (2021)."},{"key":"e_1_3_5_79_2","unstructured":"European Commission European Medicines Agency (EMA) Head of Medicines Agency. Recommendation paper on decentralised elements in clinical trials. https:\/\/health.ec.europa.eu\/system\/files\/2023-03\/mp_decentralised-elements_clinical-trials_rec_en.pdf (2022)."},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00052-3"},{"key":"e_1_3_5_81_2","unstructured":"FDA. Conduct of clinical trials of medical products during the COVID-19 public health emergency guidance for industry investigators and institutional review boards. https:\/\/www.fda.gov\/media\/136238\/download (2021)."},{"key":"e_1_3_5_82_2","unstructured":"Swissmedic. Information sheet clinical investigations with medical devices. 2022. https:\/\/www.bing.com\/ck\/a?!&&p=11a7e30d6db672dbJmltdHM9MTY4OTU1MjAwMCZpZ3VpZD0zOTkzMDczYy1hMTkwLTYwN2ItMjIxNy0xNTQ0YTAyYTYxN2ImaW5zaWQ9NTE4MQ&ptn=3&hsh=3&fclid=3993073c-a190-607b-2217-1544a02a617b&psq=Information+sheet+Clinical+investigations+with+medical+devices&u=a1aHR0cHM6Ly93d3cuc3dpc3NtZWRpYy5jaC9kYW0vc3dpc3NtZWRpYy9kZS9kb2t1bWVudGUvbWVkaXppbnByb2R1a3RlL21lcF91cnIvYnc2MDBfMDBfMDE1ZF9tYl9rbGluaXNjaGVfdmVyc3VjaGVfbWVwLnBkZi5kb3dubG9hZC5wZGYvQlc2MDBfMDBfMDE1ZV9NQl9DbGluaWNhbF9pbnZlc3RpZ2F0aW9uc193aXRoX21lZGljYWxfZGV2aWNlcy5wZGY&ntb=1"},{"issue":"18","key":"e_1_3_5_83_2","first-page":"6418","article-title":"Ethics of digital therapeutics (DTx)","volume":"26","author":"Refolo P","year":"2022","unstructured":"Refolo P, Sacchini D, Raimondi C, et al. Ethics of digital therapeutics (DTx). Eur Rev Med Pharmacol Sci 2022; 26(18): 6418\u20136423.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.07.011"},{"key":"e_1_3_5_85_2","unstructured":"CDC. Health insurance portability and accountability act of 1996 (HIPAA). https:\/\/www.cdc.gov\/phlp\/publications\/topic\/hipaa.html#:\u223c:text=TheHealthInsurancePortabilityandAccountabilityActof beingdisclosedwithoutthepatient%E2%80%99sconsentorknowledge"},{"key":"e_1_3_5_86_2","unstructured":"Regulation (EU) 2016\/679 of the European parliament and of the council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data and repealing directive 95\/46\/EC (General data protection regulation). http:\/\/data.europa.eu\/eli\/reg\/2016\/679\/oj"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.3233\/SHTI220066"},{"key":"e_1_3_5_88_2","unstructured":"HIPPA. https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-C\/part-164"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00055-9"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12481"},{"key":"e_1_3_5_91_2","unstructured":"Center for Devices and Radiological Health (CDRH). Manufacturers sharing patient_specific information from medical devices with patients upon request guidance for industry and food and drug administration staff [Internet]. https:\/\/www.fda.gov\/media\/98519\/download (2017)."},{"key":"e_1_3_5_92_2","unstructured":"Medical Device Coordination Group. MDCG 2019-16 Rev.1 guidance on cybersecurity for medical devices. https:\/\/health.ec.europa.eu\/system\/files\/2022-01\/md_cybersecurity_en.pdf (2019)."},{"key":"e_1_3_5_93_2","unstructured":"IMDRF. Principles and practices for medical device cybersecurity. https:\/\/www.imdrf.org\/sites\/default\/files\/docs\/imdrf\/final\/technical\/imdrf-tech-200318-pp-mdc-n60.pdf (2020)."},{"key":"e_1_3_5_94_2","unstructured":"IMDRF. Principles and practices for the cybersecurity of legacy medical devices. https:\/\/www.imdrf.org\/sites\/default\/files\/2022-05\/IMDRFCybersecurityproposeddocumentPDF.pdf (2022)."},{"key":"e_1_3_5_95_2","unstructured":"FDA. Cybersecurity. 2023. https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/cybersecurity"}],"container-title":["Health Informatics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14604582251387656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/14604582251387656","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14604582251387656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:29:02Z","timestamp":1777501742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/14604582251387656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/14604582251387656"],"URL":"https:\/\/doi.org\/10.1177\/14604582251387656","relation":{},"ISSN":["1460-4582","1741-2811"],"issn-type":[{"value":"1460-4582","type":"print"},{"value":"1741-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"14604582251387656"}}